1. A Pharmacokinetic and Safety Study of Trebananib, an Fc‐Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction. Issue 2 (9th June 2017) Authors: Wu, B; Lewis, LD; Harvey, RD; Rasmussen, E; Gamelin, E; Sun, Y‐N; Friberg, G; Koyner, JL; Dowlati, A; Maitland, ML Journal: Clinical pharmacology & therapeutics Issue: Volume 102:Issue 2(2017) Page Start: 313 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗